Published in Br J Cancer on October 14, 2008
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer. Diagn Pathol (2013) 0.93
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma. Br J Cancer (2009) 0.90
Functional role of kallikrein 6 in regulating immune cell survival. PLoS One (2011) 0.89
Serum tumor markers in pancreatic cancer-recent discoveries. Cancers (Basel) (2010) 0.86
Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients. Mol Cancer (2015) 0.82
Identification of human tissue kallikrein 6 as a potential marker of laryngeal cancer based on the relevant secretory/releasing protein database. Dis Markers (2014) 0.75
Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer. Biol Chem (2016) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 23.17
Human protein reference database--2006 update. Nucleic Acids Res (2006) 12.16
Metastasis: recent discoveries and novel treatment strategies. Lancet (2007) 3.93
Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol (2006) 3.26
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch (2003) 2.53
The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer (2004) 2.38
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med (2003) 1.97
Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem (2007) 1.66
Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res (2004) 1.63
Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol (2006) 1.38
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol (2003) 1.37
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol (2004) 1.21
Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J Biol Chem (2002) 1.21
Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch (2003) 1.18
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors. Biochem Biophys Res Commun (2003) 1.14
Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer. Clin Cancer Res (2005) 1.06
Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res (2007) 0.97
The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J Histochem Cytochem (2001) 0.96
In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res (2004) 0.96
Structural templates predict novel protein interactions and targets from pancreas tumour gene expression data. Bioinformatics (2007) 0.88
Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma. Tumour Biol (2005) 0.87
Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis (2003) 0.85
Human kallikrein 10, a predictive marker for breast cancer. Biol Chem (2006) 0.83
Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs (2000) 0.82
Human kallikrein 10 expression in normal tissues by immunohistochemistry. J Histochem Cytochem (2002) 0.82
Immunohistochemical localization of human kallikreins 6 and 10 in pancreatic islets. Histochem J (2003) 0.79
Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum. J Biol Chem (2000) 3.40
Several "pathogenesis-related" proteins in potato are 1,3-beta-glucanases and chitinases. Proc Natl Acad Sci U S A (1988) 3.10
Randomized clinical trial of vertical or transverse laparotomy for abdominal aortic aneurysm repair. Br J Surg (2005) 2.82
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene (2006) 2.36
Direct measurement of angles between bond vectors in high-resolution NMR. Science (1997) 2.18
The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta (1995) 2.06
Resveratrol: a molecule whose time has come? And gone? Clin Biochem (1997) 1.96
GermOnline, a cross-species community knowledgebase on germ cell differentiation. Nucleic Acids Res (2004) 1.90
Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. Urology (1999) 1.87
Prostate-specific antigen in milk of lactating women. Clin Chem (1995) 1.79
Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol (1994) 1.78
X-ray structure of junctional adhesion molecule: structural basis for homophilic adhesion via a novel dimerization motif. EMBO J (2001) 1.75
The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol (1996) 1.73
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Saccharomyces cerevisiae GATA sequences function as TATA elements during nitrogen catabolite repression and when Gln3p is excluded from the nucleus by overproduction of Ure2p. J Biol Chem (2000) 1.68
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Multianalyte immunoassay based on spatially distinct fluorescent areas quantified by laser-excited solid-phase time-resolved fluorometry. Clin Chem (1992) 1.61
Immunochemical characterization and quantitative distribution of pancreatic stone protein in sera and pancreatic secretions in pancreatic disorders. Gastroenterology (1990) 1.60
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res (1996) 1.59
Monoclonal antibodies specific for murine IgM I. Characterization of antigenic determinants on the four constant domains of the mu heavy chain. Eur J Immunol (1984) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene (2000) 1.56
Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation. J Neurosci (1997) 1.55
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 1.55
The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer (2001) 1.54
Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer (1994) 1.53
Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts. J Natl Cancer Inst (1997) 1.50
The 1.8 A resolution structure of hevamine, a plant chitinase/lysozyme, and analysis of the conserved sequence and structure motifs of glycosyl hydrolase family 18. J Mol Biol (1996) 1.49
Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal (1997) 1.48
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
Risk factors associated with alterations in carotid intima-media thickness in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis. J Hypertens (1998) 1.46
Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res (2001) 1.44
Another member of the cyclic nucleotide-gated channel family, expressed in testis, kidney, and heart. Proc Natl Acad Sci U S A (1994) 1.44
Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer (1997) 1.44
Functional imaging in PNH caused by a new FilaminA mutation. Neurology (2004) 1.43
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer (2008) 1.41
[Organ preservation in advanced laryngeal and hypopharyngeal carcinoma by primary radiochemotherapy. Results of a multicenter phase II study]. HNO (2002) 1.41
CUB and zona pellucida-like domain-containing protein 1 (CUZD1): a novel serological biomarker for ovarian cancer. Clin Biochem (2012) 1.40
Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia (2006) 1.40
Prostate-specific antigen in cerebrospinal fluid. Clin Chem (1997) 1.39
Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer (1994) 1.39
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res (1995) 1.38
Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res (1997) 1.36
Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens (2001) 1.36
Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon. J Mol Biol (2000) 1.36
Crystal structure and reaction mechanism of 7,8-dihydroneopterin aldolase from Staphylococcus aureus. Nat Struct Biol (1998) 1.35
NMR solution structure of a complex of calmodulin with a binding peptide of the Ca2+ pump. Biochemistry (1999) 1.33
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32
Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol (2007) 1.32
Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer (2005) 1.31
High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol (2000) 1.30
The new kallikrein-like gene, KLK-L2. Molecular characterization, mapping, tissue expression, and hormonal regulation. J Biol Chem (1999) 1.30
Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem (1994) 1.29
Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem (1992) 1.28
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res (1998) 1.28
Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology (2004) 1.28
An automated "high-pressure" liquid-chromatographic assay for hemoglobin A1c. Clin Chem (1984) 1.27
Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat (1996) 1.27
Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev (1998) 1.26
Structural analysis and activation by fungal infection of a gene encoding a pathogenesis-related protein in potato. Mol Plant Microbe Interact (1991) 1.26
Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett (1991) 1.26
[Quality and the profit situation in ambulatory radiotherapy]. Strahlenther Onkol (1996) 1.25
Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer (2003) 1.25
Generalized CNS disease and massive GM1-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum Mol Genet (1997) 1.24
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer (2003) 1.24
Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. Pharmacol Ther (1995) 1.24
Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer (2007) 1.23
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Germ tubes and proteinase activity contribute to virulence of Candida albicans in murine peritonitis. Infect Immun (1999) 1.22
13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol (2000) 1.21
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer (2008) 1.21
The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer (1996) 1.21
Continuous mannose infusion in carbohydrate-deficient glycoprotein syndrome type I. Acta Paediatr (1997) 1.20
Tumor necrosis factor alpha induces the expression of transforming growth factor alpha and the epidermal growth factor receptor in human pancreatic cancer cells. Proc Natl Acad Sci U S A (1993) 1.20
Search for new physics in the multijet and missing transverse momentum final state in proton-proton collisions at √s = 7 TeV. Phys Rev Lett (2012) 1.19
Azimuthal anisotropy of charged particles at high transverse momenta in Pb-Pb collisions at sqrt[s(NN)] = 2.76 TeV. Phys Rev Lett (2012) 1.19
New biological functions of prostate-specific antigen? J Clin Endocrinol Metab (1995) 1.19
Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol (1998) 1.18
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer (2005) 1.15
Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta (1996) 1.15
Insulin-like growth factor-binding protein-3 and breast cancer survival. Int J Cancer (1998) 1.14
Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res (2010) 1.13
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene (1999) 1.13
Automation of molecular diagnostics. Clin Chem (1996) 1.13
Characterization of full-length cDNAs and the gene coding for the human GM2 activator protein. FEBS Lett (1991) 1.13
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer (2003) 1.13
Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity from prostate-specific antigen. Clin Chem (1999) 1.12
ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer (2004) 1.11
Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. J Urol (1997) 1.11
Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res (1998) 1.11
Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology (2000) 1.10
Search for a W' or techni-ρ decaying into WZ in pp Collisions at sqrt[s] = 7 TeV. Phys Rev Lett (2012) 1.10
CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene (2001) 1.10